Lenalidomide in myeloma
- PMID: 17713723
- DOI: 10.1007/s11864-007-0011-7
Lenalidomide in myeloma
Abstract
The standard treatment approach to symptomatic myeloma consists of induction therapy, consolidation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation in appropriate patients, maintenance therapy, and salvage therapy. Salvage therapy is of particular importance because not all patients respond to primary therapy, and relapse is virtually universal in responding patients. Newer agents such as thalidomide, bortezomib, and lenalidomide are very active in patients with relapsed or refractory disease. Their use singly and in combination results in excellent cytoreduction including complete remissions in patients relapsing - even after extensive prior therapy. These novel agents have been usually used as salvage therapy in patients relapsing after standard treatment options including transplantation; a setting in which they are thought to improve survival. However, there is an increasing trend to start using them early in the course of the disease; for induction therapy. While early deployment of these agents is certainly associated with high-response rates, evidence that this improves long-term outcome (survival) in patients who subsequently undergo intensive therapy and transplantation is lacking. Toxicity, expense, and possible long-term consequences on the biology of the disease (for example, development of refractory relapse) remain a concern. The most appropriate use of newer agents such as lenalidomide is as salvage therapy of relapsed or refractory disease, and their use as part of induction therapy should be confined to clinical trials until additional data and long-term follow-up are available.
Similar articles
-
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.Semin Hematol. 2005 Oct;42(4 Suppl 4):S9-15. doi: 10.1053/j.seminhematol.2005.10.004. Semin Hematol. 2005. PMID: 16344100 Review.
-
Treatment of multiple myeloma: 2009 update.Prescrire Int. 2009 Dec;18(104):263-6. Prescrire Int. 2009. PMID: 20025098
-
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.Haematologica. 2013 May;98(5):776-83. doi: 10.3324/haematol.2012.069328. Epub 2012 Nov 9. Haematologica. 2013. PMID: 23144198 Free PMC article.
-
Lenalidomide in multiple myeloma.Best Pract Res Clin Haematol. 2007 Dec;20(4):717-35. doi: 10.1016/j.beha.2007.09.002. Best Pract Res Clin Haematol. 2007. PMID: 18070715 Review.
-
Lenalidomide and its role in the management of multiple myeloma.Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865. Expert Rev Anticancer Ther. 2008. PMID: 18533796 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical